Literature DB >> 22521775

Differential effects of chronic hyperammonemia on modulation of the glutamate-nitric oxide-cGMP pathway by metabotropic glutamate receptor 5 and low and high affinity AMPA receptors in cerebellum in vivo.

Andrea Cabrera-Pastor1, Marta Llansola, Vitaliy Reznikov, Jordi Boix, Vicente Felipo.   

Abstract

Previous studies show that chronic hyperammonemia impairs learning ability of rats by impairing the glutamate-nitric oxide (NO)-cyclic guanosine mono-phosphate (cGMP) pathway in cerebellum. Three types of glutamate receptors cooperate in modulating the NO-cGMP pathway: metabotropic glutamate receptor 5 (mGluR5), (RS)-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and N-methyl-d-aspartic acid (NMDA) receptors. The aim of this work was to assess whether hyperammonemia alters the modulation of this pathway by mGluR5 and AMPA receptors in cerebellum in vivo. The results support that in control rats: (1) low AMPA concentrations (0.1mM) activate nearly completely Ca(2+)-permeable (glutamate receptor subunit 2 (GluR2)-lacking) AMPA receptors and the NO-cGMP pathway; (2) higher AMPA concentrations (0.3 mM) also activate Ca(2+)-impermeable (GluR2-containing) AMPA receptors, leading to activation of NMDA receptors and of NO-cGMP pathway. Moreover, the data support that chronic hyperammonemia: (1) reduces glutamate release and activation of the glutamate-NO-cGMP pathway by activation of mGluR5; (2) strongly reduces the direct activation by AMPA receptors of the NO-cGMP pathway, likely due to reduced entry of Ca(2+) through GluR2-lacking, high affinity AMPA receptors; (3) strongly increases the indirect activation of the NO-cGMP pathway by high affinity AMPA receptors, likely due to increased entry of Na(+) through GluR2-lacking AMPA receptors and NMDA receptors activation; (4) reduces the indirect activation of the NO-cGMP pathway by low affinity AMPA receptors, likely due to reduced activation of NMDA receptors.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22521775     DOI: 10.1016/j.neuint.2012.04.006

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  4 in total

Review 1.  Chronic hyperammonemia, glutamatergic neurotransmission and neurological alterations.

Authors:  Marta Llansola; Carmina Montoliu; Omar Cauli; Vicente Hernández-Rabaza; Ana Agustí; Andrea Cabrera-Pastor; Carla Giménez-Garzó; Alba González-Usano; Vicente Felipo
Journal:  Metab Brain Dis       Date:  2012-09-26       Impact factor: 3.584

2.  Hyperammonemia Alters the Function of AMPA and NMDA Receptors in Hippocampus: Extracellular cGMP Reverses Some of These Alterations.

Authors:  María Sancho-Alonso; Lucas Taoro-Gonzalez; Andrea Cabrera-Pastor; Vicente Felipo; Vicent Teruel-Martí
Journal:  Neurochem Res       Date:  2022-04-06       Impact factor: 3.996

3.  A multi-omic study for uncovering molecular mechanisms associated with hyperammonemia-induced cerebellar function impairment in rats.

Authors:  Sonia Tarazona; Héctor Carmona; Ana Conesa; Marta Llansola; Vicente Felipo
Journal:  Cell Biol Toxicol       Date:  2021-01-06       Impact factor: 6.691

4.  Fisetin ameliorates oxidative glutamate testicular toxicity in rats via central and peripheral mechanisms involving SIRT1 activation.

Authors:  Fatma H Rizk; Nema A Soliman; Suzan E Abo-Elnasr; Heba A Mahmoud; Muhammad T Abdel Ghafar; Rasha A Elkholy; Ola A ELshora; Reham A Mariah; Shaimaa Samir Amin Mashal; Amira A El Saadany
Journal:  Redox Rep       Date:  2022-12       Impact factor: 5.696

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.